Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ORIC Oric Pharmaceuticals Inc.

Trading 02-06 14:13:08 EST

10.55

+0.59

+5.87%

High10.66	Low9.99	Vol943.96K
Open10.36	D1 Closing9.96	Amplitude6.73%
Mkt Cap1.03B	Tradable Cap639.65M	Total Shares97.39M
T/O9.75M	T/O Rate1.56%	Tradable Shares60.66M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ORIC","market":"US","secType":"STK","nameCN":"Oric Pharmaceuticals Inc.","latestPrice":10.545,"timestamp":1770405176634,"preClose":9.96,"halted":0,"volume":943959,"delay":0,"changeRate":0.05873493975903605,"floatShares":60659100,"shares":97389279,"eps":-1.69572,"marketStatus":"Trading","change":0.585,"latestTime":"02-06 14:13:08 EST","open":10.355,"high":10.66,"low":9.99,"amount":9748763.947311,"amplitude":0.067269,"askPrice":10.55,"askSize":240,"bidPrice":10.53,"bidSize":346,"shortable":3,"etf":0,"ttmEps":-1.69572,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770411600000},"marketStatusCode":2,"adr":0,"listingDate":1587700800000,"exchange":"NASDAQ","adjPreClose":9.96,"preHourTrading":{"tag":"盘前","latestPrice":10.17,"preClose":9.96,"latestTime":"09:28 EST","volume":4578,"amount":46220.234214000004,"timestamp":1770388080064,"change":0.21,"changeRate":0.021084,"amplitude":0.111446},"postHourTrading":{"tag":"盘后","latestPrice":9.77,"preClose":9.96,"latestTime":"18:46 EST","volume":15960,"amount":158922.91,"timestamp":1770335175171,"change":-0.19,"changeRate":-0.019076,"amplitude":0.019076},"volumeRatio":0.888798,"impliedVol":0.7909,"impliedVolPercentile":0.4183},"requestUrl":"/m/hq/s/ORIC/wiki","defaultTab":"wiki","newsList":[{"id":"2609581692","title":"ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2609581692","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609581692?lang=en_us&edition=fundamental","pubTime":"2026-02-06 05:01","pubTimestamp":1770325260,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb.  05, 2026  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that addres","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/05/3233410/0/en/ORIC-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"gpt_icon":0},{"id":"2605286851","title":"Oric Pharmaceuticals Director Richard A. Heyman Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605286851","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605286851?lang=en_us&edition=fundamental","pubTime":"2026-01-21 08:19","pubTimestamp":1768954795,"startTime":"0","endTime":"0","summary":"Richard A. Heyman, Director at Oric Pharmaceuticals Inc, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL3kXLCh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oric Pharmaceuticals Director Richard A. Heyman Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"gpt_icon":0},{"id":"2603083648","title":"ORIC Pharmaceuticals: Dense Near‑Term Clinical Catalysts and Encouraging Efficacy Data Underpin Reiterated Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2603083648","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603083648?lang=en_us&edition=fundamental","pubTime":"2026-01-15 00:25","pubTimestamp":1768407952,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on ORIC stock, giving a Buy rating today. Robert Burns has given his Buy r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/oric-pharmaceuticals-dense-near‑term-clinical-catalysts-and-encouraging-efficacy-data-underpin-reiterated-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/oric-pharmaceuticals-dense-near‑term-clinical-catalysts-and-encouraging-efficacy-data-underpin-reiterated-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC"],"gpt_icon":0},{"id":"2603638942","title":"Wedbush Sticks to Their Buy Rating for Oric Pharmaceuticals (ORIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603638942","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603638942?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:38","pubTimestamp":1768315124,"startTime":"0","endTime":"0","summary":"In a report released today, from Wedbush maintained a Buy rating on Oric Pharmaceuticals, with a price target of $20.00. In addition to Wedbush, Or...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-their-buy-rating-for-oric-pharmaceuticals-oric-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-their-buy-rating-for-oric-pharmaceuticals-oric-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC"],"gpt_icon":0},{"id":"2603682702","title":"Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2603682702","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603682702?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:44","pubTimestamp":1768311840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ORIC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2026 08:44 ET (13:44 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"gpt_icon":0},{"id":"2602548180","title":"Oric Pharmaceuticals Raises $244 Million in Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2602548180","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602548180?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:31","pubTimestamp":1768224692,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals Inc. announced that it has raised $244 million from top-tier healthcare specialist funds through a private placement and under its at-the-market  program throughout 2025. The funds have strengthened the company’s cash position, providing a financial runway expected to last into the second half of 2028 and beyond key clinical milestone readouts.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via GlobeNewswire  on January 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL40xs0j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4139","SG9999014039.USD","LU2210149790.SGD","NDAQ","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2095319765.USD","ORIC","SG9999014005.SGD","IE00BKPKM429.USD","BK4588","LU0314104364.USD"],"gpt_icon":0},{"id":"2602754894","title":"Oric Pharmaceuticals Appoints Kevin Brodbeck as Chief Technical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2602754894","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602754894?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:30","pubTimestamp":1768224622,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals Inc. announced the appointment of Kevin Brodbeck, PhD, to the newly established role of Chief Technical Officer .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via GlobeNewswire  on January 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL15JZvn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014013.SGD","LU2095319765.USD","BK4139","LU2210150020.SGD","SG9999014039.USD","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","SG9999014005.SGD","BK4588","LU2210149790.SGD","LU0314104364.USD","BK4585","SG9999014021.USD","IE00BKPKM429.USD","ORIC"],"gpt_icon":0},{"id":"2602543526","title":"ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543526","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543526?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:30","pubTimestamp":1768224600,"startTime":"0","endTime":"0","summary":"Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216908/0/en/ORIC-Pharmaceuticals-Provides-Operational-Highlights-for-2025-and-Anticipated-Upcoming-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTO","BK4160","LU1066051225.USD","LU1066051498.USD","ORIC","LU1066051811.HKD","LU1066053197.SGD"],"gpt_icon":0},{"id":"2601805830","title":"Oric Pharmaceuticals Initiated at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2601805830","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601805830?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:13","pubTimestamp":1767791580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ORIC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 07, 2026 08:13 ET (13:13 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"gpt_icon":0},{"id":"2601808939","title":"Piper Sandler Initiates ORIC Pharmaceuticals Inc at Overweight With $22 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2601808939","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601808939?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:36","pubTimestamp":1767789373,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals Inc (ORIC) has an average rating of buy and mean price target of $21, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ORIC"],"gpt_icon":0},{"id":"2601969845","title":"ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601969845","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601969845?lang=en_us&edition=fundamental","pubTime":"2026-01-07 05:05","pubTimestamp":1767733500,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan.  06, 2026  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that addres","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/06/3214126/0/en/ORIC-Pharmaceuticals-to-Present-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2271345857.HKD","LU1791710400.SGD","LU1668664300.SGD","LU0795875169.SGD","BK4516","IE00BKVL7J92.USD","LU0106831901.USD","LU0528227936.USD","LU0795875086.SGD","LU1989772840.SGD","LU0971096721.USD","XBI","LU0314104364.USD","LU0029874061.USD","HCSG","LU2347655156.SGD","LU0098860793.USD","LU0882574139.USD","LU2028103732.USD","LU1074936037.SGD","LU0106261372.USD","LU1162221912.USD","LU0006306889.USD","LU0267386448.USD","ORIC","LU0557290698.USD","LU1363072403.SGD","LU2133065610.SGD","XLV","LABU","LU2023251221.USD","BK4504","BK4137","BK4127","LU2089284900.SGD","LU1732799900.SGD","BK4588","LU0158827948.USD","BK4581","IE00BZ1G4Q59.USD","LU0320765646.SGD","LU1244550221.USD","LU1244550494.USD","LU1989772923.USD","LU2111349929.HKD","LU0912757837.SGD","LU1732800096.USD","LU1720051108.HKD","LU1244550577.SGD","LU0225283273.USD"],"gpt_icon":0},{"id":"2595672765","title":"BUZZ-India's Orient Technologies rises after shareholders approve bonus issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2595672765","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595672765?lang=en_us&edition=fundamental","pubTime":"2025-12-30 12:24","pubTimestamp":1767068665,"startTime":"0","endTime":"0","summary":"BUZZ-India's Orient Technologies rises after shareholders approve bonus issue** Shares of Orient Technologies Ltd ORIC.NS rise as much as 12.4% to 372 rupees ** IT co says its shareholders have approved bonus issue of shares in ratio of 1:10** More than 3 mln shares traded as of 9:51 A.M. IST, 14.7x their 30-day moving avg; busiest day yet since Oct. 7** ORIC down 31.2% YTD so far ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nL6N3Y0035:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"gpt_icon":0},{"id":"2592934737","title":"Oric Pharmaceuticals Currently Down Eight Consecutive Days, On Track for Longest Losing Streak Since June 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2592934737","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592934737?lang=en_us&edition=fundamental","pubTime":"2025-12-17 03:41","pubTimestamp":1765914060,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals, Inc.  is currently at $9.04, down $0.19 or 2%. --Would be lowest close since June 17, 2025, when it closed at $9.03. --Currently down eight consecutive days; down 20.59% over this period. --Longest losing streak since June 20, 2024, when it fell for 10 straight trading days. --Up 12.08% year-to-date; on pace for best year since 2023, when it rose 56.2%. --Down 77.27% from its all-time closing high of $39.80 on Dec. 24, 2020. --Up 9.64% from 52 weeks ago , when it closed at $8.25. --Down 37.23% from its 52-week closing high of $14.41 on Oct. 6, 2025. --Up 112.57% from its 52-week closing low of $4.26 on April 8, 2025. --Traded as low as $8.82; lowest intraday level since June 4, 2025, when it hit $8.16","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"gpt_icon":0},{"id":"2590453153","title":"ORIC Pharmaceuticals (ORIC): Valuation Check After Encouraging Enozertinib Phase 1b Lung Cancer Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2590453153","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590453153?lang=en_us&edition=fundamental","pubTime":"2025-12-09 17:12","pubTimestamp":1765271541,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals (ORIC) is back in the spotlight after unveiling fresh Phase 1b data for its lung cancer drug enozertinib at ESMO Asia 2025, highlighting systemic and intracranial activity in difficult EGFR and HER2 mutation settings.\nSee our latest analysis for ORIC Pharmaceuticals.\nThe string of upbeat enozertinib updates, analyst support and recent conference exposure comes against a choppy tape, with a weaker 1 month share price return but still a strong year to date share price gain...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/oric-pharmaceuticals-oric-valuation-check-after-encouraging","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/oric-pharmaceuticals-oric-valuation-check-after-encouraging","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ORIC","BK4139"],"gpt_icon":0},{"id":"2589359854","title":"Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2589359854","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589359854?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:18","pubTimestamp":1765203480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ORIC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 09:18 ET (14:18 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"gpt_icon":0},{"id":"2589810692","title":"Oric Pharmaceuticals Grants Stock Options and Restricted Stock Units to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2589810692","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589810692?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:30","pubTimestamp":1764970209,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals Inc. has granted a total of 69,200 non-qualified stock options and 11,400 restricted stock units to three new non-executive employees who joined the company in November 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via GlobeNewswire  on December 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL6vl6X8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","ORIC","LU0314104364.USD","BK4139","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4112","LU2210149790.SGD","NDAQ","BK4588","IE00B64PRP62.GBP","BK4585","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2589699810","title":"Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589699810","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589699810?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:30","pubTimestamp":1764970200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nTUA8LSSZD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORIC","BK4139"],"gpt_icon":0},{"id":"2589810432","title":"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589810432","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589810432?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:30","pubTimestamp":1764970200,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec.  05, 2025  (GLOBE NEWSWIRE) --  ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that addres","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/05/3200990/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"gpt_icon":0},{"id":"2589785273","title":"Oric Pharmaceuticals Reports Promising Phase 1b Results for Enozertinib in NSCLC Patients with EGFR Mutations","url":"https://stock-news.laohu8.com/highlight/detail?id=2589785273","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589785273?lang=en_us&edition=fundamental","pubTime":"2025-12-05 10:45","pubTimestamp":1764902714,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals Inc. announced data from a Phase 1b trial of enozertinib  at the ESMO Asia Congress 2025. The results, which have already been presented, included findings in previously treated non-small cell lung cancer  patients with EGFR atypical mutations and preliminary data in first-line NSCLC patients with EGFR P-loop and alpha C-helix compressing  mutations. The study reported an 80% overall response rate  and 100% intracranial ORR in first-line EGFR PACC patients, as well as a 36% ORR in later-line EGFR PACC patients. Enozertinib was reported to have a competitive safety profile with manageable toxicity and a low discontinuation rate. Further enrollment and follow-up in first-line EGFR PACC patients are ongoing at a selected dose, with the next data update expected in mid-2026 ahead of a potential Phase 3 trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDLbZ86vF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0314104364.USD","BK4112","BK4585","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","LU2210150020.SGD","ORIC","BK4139","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2589857841","title":"ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2589857841","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589857841?lang=en_us&edition=fundamental","pubTime":"2025-12-05 10:45","pubTimestamp":1764902700,"startTime":"0","endTime":"0","summary":"Highly differentiated 1L EGFR PACC preliminary systemic activity of 80% ORR and 100% intracranial ORR, including in patients with active brain metastases 36% ORR in median 3L EGFR PACC patients exceed","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/05/3200427/0/en/ORIC-Pharmaceuticals-Presents-Potential-Best-in-Class-Profile-for-Enozertinib-with-Robust-Systemic-and-CNS-Activity-in-1L-and-Previously-Treated-NSCLC-Patients-with-EGFR-Atypical-M.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4166","BK4503","CNS","ORR","QD","BK4135","ORIC","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oricpharma.com","stockEarnings":[{"period":"1week","weight":-0.0743},{"period":"1month","weight":0.2236},{"period":"3month","weight":-0.1935},{"period":"6month","weight":0.0779},{"period":"1year","weight":-0.1961},{"period":"ytd","weight":0.2176}],"compareEarnings":[{"period":"1week","weight":-0.0237},{"period":"1month","weight":-0.0205},{"period":"3month","weight":0.0099},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1215},{"period":"ytd","weight":-0.0063}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.039993},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.071168},{"month":3,"riseRate":0.4,"avgChangeRate":-0.098966},{"month":4,"riseRate":0.2,"avgChangeRate":-0.164176},{"month":5,"riseRate":0.666667,"avgChangeRate":0.07899},{"month":6,"riseRate":0.666667,"avgChangeRate":0.141043},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.000511},{"month":8,"riseRate":0.666667,"avgChangeRate":0.090659},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.048915},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.0811},{"month":11,"riseRate":0.666667,"avgChangeRate":0.167402},{"month":12,"riseRate":0.5,"avgChangeRate":0.06155}],"exchange":"NASDAQ","name":"Oric Pharmaceuticals Inc.","nameEN":"Oric Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oric Pharmaceuticals Inc.(ORIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oric Pharmaceuticals Inc.,ORIC,Oric Pharmaceuticals Inc.股票,Oric Pharmaceuticals Inc.股票老虎,Oric Pharmaceuticals Inc.股票老虎国际,Oric Pharmaceuticals Inc.行情,Oric Pharmaceuticals Inc.股票行情,Oric Pharmaceuticals Inc.股价,Oric Pharmaceuticals Inc.股市,Oric Pharmaceuticals Inc.股票价格,Oric Pharmaceuticals Inc.股票交易,Oric Pharmaceuticals Inc.股票购买,Oric Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oric Pharmaceuticals Inc.(ORIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction